PMC3573788_01
A PET scan showing a mediastinal mass before IL-2 therapy (a) and the same area without the mass after IL-2 therapy (b).
cro-0006-0078-g01.jpg
PMC3573788_01_cro-0006-0078-g01.jpg
F1
A positron emission tomography/CT (PET/CT) scan confirmed the presence of a highly metabolically active tumor at the site (fig. 1a). A follow-up PET/CT scan showed resolution of the metastatic disease in the chest (fig. 1b).
A brain MRI scan showing an enhancing lesion before Gamma Knife therapy (a) and the same area 3 months (b) and 5 months (c) after Gamma Knife therapy.
cro-0006-0078-g02.jpg
PMC3573788_01_cro-0006-0078-g02.jpg
F2
However, a follow-up brain MRI scan showed that the previously detected lesion was increasing in size (fig. 2a). Serial imaging scans have not shown any evidence of melanoma recurrence, however (fig. 2b, c).